Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
66M
-
Shares change
-
+314K
-
Total reported value, excl. options
-
$447M
-
Value change
-
+$3.69M
-
Put/Call ratio
-
0
-
Number of buys
-
72
-
Number of sells
-
-71
-
Price
-
$6.77
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2021
175 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2021.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66M shares
of 123M outstanding shares and own 53.59% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (9.57M shares), BlackRock Inc. (7.68M shares), STATE STREET CORP (5.05M shares), VANGUARD GROUP INC (4.84M shares), LSV ASSET MANAGEMENT (4.05M shares), ROYCE & ASSOCIATES LP (2.58M shares), DIMENSIONAL FUND ADVISORS LP (1.9M shares), GEODE CAPITAL MANAGEMENT, LLC (1.73M shares), NORTHERN TRUST CORP (1.38M shares), and ACADIAN ASSET MANAGEMENT LLC (1.38M shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.